Navigation Links
Drug Combo Halves Death Risk for Severe COPD Patients
Date:12/28/2007

Salmeterol plus fluticasone therapy led to better health, large trial finds

FRIDAY, Dec. 28 (HealthDay News) -- People suffering with chronic obstructive pulmonary disease (COPD) may find that combining two currently available medications halves their risk of death within two years as well and improves their overall health status and quality of life, new research suggests.

The conclusion is drawn from the first human trial to compare treatment of COPD with a combination of salmeterol and fluticasone [SFC] to tiotropium therapy. The medications in the study are currently prescribed to improve breathing among patients with COPD or asthma.

COPD, a chronic disease that makes it difficult to breathe easily, is the fourth leading cause of death in the United States. More than 11 million people are diagnosed with the condition, according to the American Lung Association.

"Although we found no difference in the overall rate of exacerbations between treatment groups, SFC treatment was associated with better health status, fewer patient withdrawals, and a lower mortality rate than occurred during tiotropium therapy," study author Dr. Jadwiga Wedzicha, of the Royal Free & University College Medical School in London, said in a prepared statement.

Writing in the January issue of the American Journal of Respiratory and Critical Care Medicine, researchers described the results of a two-year trial of SFC or tiotropium for 1,323 patients with severe COPD. The researchers analyzed number and type of exacerbations, health status, lung function and study withdrawal rate. Patients were randomly assigned to one of the two treatment plans, and neither they nor their doctors knew which treatment they were receiving.

Exacerbations are periods of time when people with COPD have a harder time breathing freely, characterized by wheezing, coughing and shortness of breath. People may need medical assistance during an exacerbation. Neither treatment was more successful in reducing the number of exacerbations patients experienced, although the researchers noted that oral steroids were used more often to control exacerbations among people taking tiotropium. People on SFC were more likely to require antibiotics.

However, patients in the SFC arm of the trial were 50 percent less likely to die from any cause during the two years of the study. They were also less likely to drop out of the trial.

The researchers called for further research to understand the mechanisms behind the therapies.

More information

To learn more about COPD, visit the American Lung Association.



-- Madeline Vann



SOURCE: American Thoracic Society, news release, Dec. 28, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Radiation and drug combo helps boost efficacy of lung cancer treatment
2. Aerobic, Weight Training Combo Best Against Diabetes
3. New antibiotic drug combo to speed up treatment of tuberculosis
4. Drug Combo Helps Fight Marfan Syndrome
5. Drug Combo Blocks Pain Without Impairing Movement
6. Two-Drug Combo Fights Brain Tumors
7. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
8. Drug Combo Boosts Multiple Myeloma Survival
9. Drug Combos Effective Against Rheumatoid Arthritis
10. Combo PET/CT Scan Helps Spot Breast Cancers Spread
11. Drug Combo With Antibiotic May Slow MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any ... useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, templates with ... speed' and the need to operate in a GLP (Good Laboratory Practice) fashion. , ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... They are ... are sisters and wives, brothers and fathers, from New England and around the nation. ... its stigma, and are brought together in a beautiful and compelling new photographic exhibit ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial consultation services to residents in the Sacramento/Folsom region, is initiating ... Chance treatment facility. , The Another Choice Another Chance treatment center in Sacramento ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... 2016 Global Cervical Dysplasia Market: Scope ... cervical dysplasia market analyzes the current and future ... elaborate executive summary, including a market snapshot that ... The research is a combination of primary ... of our research efforts along with information collected ...
(Date:12/7/2016)... , Dec. 7, 2016 REPORT ... Market Intelligence (2011-2020)" provides market intelligence on a ... forecast (2011-2020) has been provided in the report. ... provide 1) comprehensive global market intelligence through detailed ... market dynamics, industry structure and developments, market situation, ...
Breaking Medicine Technology: